ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "rheumatoid arthritis (RA) and treatment"

  • Abstract Number: 2385 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Chinese Herbal Medicine Biqi Capsule Combined with Methotrexate in Patients with Rheumatoid Arthritis: A Pilot Study

    Runyue Huang1, Qingchun Huang 2, Jiaqi Wu 3, Xiao Cai 4, Xiumin Chen 4, Yue Zhao 4, Yongliang Chu 2, Jianyong Zhang 5, Jianhong Peng 6, Zhisheng Huang 7, Xianghong Chen 2, Zehao Liu 8 and Aihua Ou 2, 1The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China; Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China;, Guangzou, Guangdong, China (People's Republic), 2The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China (People's Republic), 3Section Rheumatology Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzou, China (People's Republic), 4The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzou, China (People's Republic), 5Shenzhen Hospital of Traditional Chinese Medicine, Shenzhen, China (People's Republic), 6Dongguan Hospital of Traditional Chinese Medicine, Dongguan, China (People's Republic), 7Guangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Huandu, China (People's Republic), 8Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China (People's Republic)

    Background/Purpose:  In recent years, the combination therapies of conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) with Chinses medicine has prevailed for the treatment of rheumatoid arthritis…
  • Abstract Number: 1938 • 2018 ACR/ARHP Annual Meeting

    A Phase IIb Dose-Ranging Study of Anti-GM-CSF with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate

    Chris Buckley1, Jesus A Simon Campos2, Sergey Yakushin3, Vyacheslav Zhdan4, Katherine Davy5, David Inman6, Elena Fisheleva7,8, Anubha Gupta8, Mark Layton9, Nina Mitchell7,8, Jatin Patel10, Russell Williamson6 and Paul-Peter Tak11, 1University of Birmingham, Birmingham, United Kingdom, 2Hospital CEM/BIOCEM, Merida, Mexico, 3Ryazan Regional Clinical Cardiology Dispensary, Ryazan, Russian Federation, 4M.V.Sklifosovskyi Poltava Regional Clinical Hospital, Poltava, Ukraine, 5Statistics, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, 6GlaxoSmithKline, Stockley Park, United Kingdom, 7Currently at Biomarin UK Ltd, London, United Kingdom, 8GlaxoSmithKline, Stevenage, United Kingdom, 9ImmunoInflammation, ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, 10ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, 11University of Cambridge, Cambridge and GlaxoSmithKline, Stevenage, United Kingdom

    Background/Purpose: GSK3196165 is a high-affinity anti-GM-CSF cytokine IgG mAb currently in development for RA, with reported efficacy using IV dosing. This study evaluated the efficacy…
  • Abstract Number: 1939 • 2018 ACR/ARHP Annual Meeting

    Sirolimus Treatment in Patients with Refractory Rheumatoid Arthritis: A Double-Arm, Open-Label, phase1/2 Trail

    Jia Wang1, Sheng-Xiao Zhang2, Fang-Yuan Hu3, Xiao-Juan Zheng1, Ting Cheng1, Na-Na Yu2, Wen-Xian Yang1, Chong Gao4, Hong-Yan Wen2 and Xiao-Feng Li5, 1Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, 2The Second Hospital of Shanxi Medical University, Taiyuan, China, 3Rheumatology, The Second Hospital of Shanxi Medical Univerity, Taiyuan City, China, 4Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, 5The Second Hospital of Shanxi Medical Univerity, Taiyuan, China

    Background/Purpose:  Patients with refractory rheumatoid arthritis (RA) have T-cell dysfunction that associates the activation of mTOR that is inhibited by rapamycin, which has been developed…
  • Abstract Number: 2054 • 2018 ACR/ARHP Annual Meeting

    In Rheumatoid Arthritis, Changes in Autoantibody Levels Do Not Associate with Treatment Response, but Are a Reflection of Treatment Intensity

    Emma de Moel1, Veerle Derksen1, LA Trouw1, Holger Bang2, Gerard Collée3, L.R. Lard4, Tom W.J. Huizinga5, Cornelia F. Allaart6, René E.M. Toes5 and Diane van der Woude5, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Orgentec Diagnostika GmbH, Mainz, Germany, 3Rheumatology, Haaglanden Medical Center Antoniushove, Leidschendam, Netherlands, 4Rheumatology, LUMC, Leiden, Netherlands, 5Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 6Department of Rheumatology, LUMC, Leiden, Netherlands

    Background/Purpose: Rheumatoid arthritis (RA) is characterized by the presence of autoantibodies like rheumatoid factor (RF), anti-cyclic citrullinated peptide-2 (anti-CCP2), & anti-carbamylated protein (anti-CarP) antibodies. It…
  • Abstract Number: 2344 • 2018 ACR/ARHP Annual Meeting

    Treatment Modes in Rheumatoid Arthritis: Moving Toward Shared Decision-Making

    Peter C. Taylor1, Neil Betteridge2, T Michelle Brown3, John Woolcott4, Alan J. Kivitz5, Cristiano A F Zerbini6, Diane Whalley7, Oyebimpe Olayinka-Amao3, Connie Chen8, Palle Dahl9, Dario Ponce de Leon10, David Gruben11 and Lara Fallon12, 1University of Oxford, Oxford, United Kingdom, 2Neil Betteridge Associates, London, United Kingdom, 3RTI Health Solutions, Research Triangle Park, NC, 4Pfizer Inc, Collegeville, PA, 5Altoona Center for Clinical Research, Duncansville, PA, 6Centro Paulista de Investigação Clinica, São Paulo, Brazil, 7RTI Health Solutions, Manchester, United Kingdom, 8Pfizer Inc, New York, NY, 9Pfizer Inc, Ballerup, Denmark, 10Pfizer Inc, Lima, Peru, 11Pfizer Inc, Groton, CT, 12Pfizer Canada, Montreal, QC, Canada

    Background/Purpose: Treatment recommendations in RA emphasize shared decision-making,1 but little is known about patient (pt) perspectives. Through qualitative research, we aim to understand pt preferences…
  • Abstract Number: 134 • 2018 ACR/ARHP Annual Meeting

    Exploration of T-Cell Signatures Following TCR Stimulation Using Single Cell RNA-Seq to Inform Treatment Response Studies in Rheumatoid Arthritis

    Paul Martin1, James Ding1, Ben Mulhearn1, Sebastien Viatte1 and Stephen Eyre1,2, 1Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 2NIHR Manchester Musculoskeletal Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom

    Background/Purpose: For rheumatoid arthritis (RA), as with many other rheumatic diseases, the importance of determining which therapy will work best, early in disease, to prevent…
  • Abstract Number: 2510 • 2018 ACR/ARHP Annual Meeting

    A Phase IIa Mechanistic Study of Anti-GM-CSF (GSK3196165) with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate

    Mark C. Genovese1, Mario Berkowitz2, Philip G. Conaghan3, Katherine Davy4, David Inman5, Elena Fisheleva6,7, Anubha Gupta6, Robert Janiczek6, Mark Layton8, Nina Mitchell6,7, Jatin Patel9, Julia E. Smith10, Russell Williamson5 and Paul-Peter Tak11, 1Stanford University Medical Center, Palo Alto, CA, 2Leon Medical Research, Lauderdale Lakes, FL, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Statistics, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, 5GlaxoSmithKline, Stockley Park, United Kingdom, 6GlaxoSmithKline, Stevenage, United Kingdom, 7Currently at Biomarin UK Ltd, London, United Kingdom, 8ImmunoInflammation, ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, 9ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, 10Immunoinflammation TA, GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom, 11GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom

    Background/Purpose: GSK3196165 is a high-affinity anti-GM-CSF cytokine IgG mAb currently in development for RA, with reported efficacy using IV dosing.  This study evaluated the effects…
  • Abstract Number: 555 • 2018 ACR/ARHP Annual Meeting

    Three Year Outcomes of Patients with Elderly-Onset Rheumatoid Arthritis Treated with a Therapeutic Strategy Targeting Low Disease Activity, and Impact of Adverse Events on Physical Function

    Takahiko Sugihara1, Tatsuro Ishizaki2, Hiroyuki Baba3, Takumi Matsumoto3, Shoko Iga1, Takeshi Kusuda1, Marina Tsuchida1, Mari Kamiya3, Yoji Komiya3, Fumio Hirano4, Tadashi Hosoya3, Nobuyuki Miyasaka3 and Masayoshi Harigai5, 1Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, 2Human Care Research Team, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, 3Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, 4Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Department of Rheumatology, Tokyo, Japan, 5Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan

    Background/Purpose: The aim of this study was to evaluate three year outcomes of patients with elderly-onset RA (EORA) who were treated with a therapeutic strategy…
  • Abstract Number: 2538 • 2018 ACR/ARHP Annual Meeting

    Rapamycin Induces Remission in Patients with Newly Diagnosed Rheumatoid Arthritis

    Min Chen1, Xiao-Feng Li2, Chong Gao3 and Cai-Hong Wang4, 1The Second Hospital of Shanxi Medical Univerity, Taiyuan City, China, 2Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China, 3Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, 4The Second Hospital of Shanxi Medical Univerity, Taiyuan, China

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints.We found that there was an imbalance between Th17 and Treg…
  • Abstract Number: 561 • 2018 ACR/ARHP Annual Meeting

    U-Act-Early Trial 3 Years Follow-up: Radiographic Joint Damage and Use of Bdmards over 5 Years in Early RA Patients Treated-to-Target with Strategies Initiating Tocilizumab, Methotrexate or Their Combination

    Maxime MA Verhoeven1, Maria JH de Hair2, Paco MJ Welsing2, Attila Pethö-Schramm3, Michelle EA Borm4, Xavier M Teitsma2, Jacob van Laar2, Floris PJG Lafeber2, Johannes W. J. Bijlsma5 and Johannes W. G. Jacobs6, 1Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, 3F. Hoffmann-La Roche, Basel, Switzerland, 4Roche Nederland BV, Woerden, Netherlands, 5Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 6Rheumatolgy & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: The U-Act-Early trial was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission, with step-up…
  • Abstract Number: 2540 • 2018 ACR/ARHP Annual Meeting

    Effect of Buccal Hygiene on the Systemic Activity of Patients with Rheumatoid Arthritis: A Randomized Clinical Trial

    Xavier Mariette1, Elodie Perrodeau2, Christian Verner3, Xavier Struillou4, Thierry Schaeverbeke5, Alain Cantagrel6, Philippe Ravaud7 and Philippe Bouchard8, 1Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, 2Paris Hotel Dieu, Paris, France, 3Periodontology, UFR d'odontologie, University of Nantes, Nantes, France, 4Periodontology, UFR d'odontologie, University of Nantes,, Nantes, France, 5Rheumatology, CHU Bordeaux, Bordeaux, France, 6Rheumatology, CHU Toulouse, Toulouse, France, 7INSERM UMR1153, Paris Descartes University, Paris, France, 8Paris Diderot University, Paris, France

    Background/Purpose: Good evidence suggests a relationship between rheumatoid arthritis (RA) and periodontitis. We aimed to investigate if a good oral hygiene could improve activity of…
  • Abstract Number: 577 • 2018 ACR/ARHP Annual Meeting

    Expanded Autoantibody Profiles Predict Treatment Response to Biologic Therapy in Rheumatoid Arthritis

    Ted R. Mikuls1, Amrita Bath2, Bryant R. England3, Michael J. Duryee4, Carlos D. Hunter4, Joel Kremer5, Dimitrios A. Pappas6,7, William H. Robinson8, Jeffrey R. Curtis9 and Geoffrey M. Thiele10, 1Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 2Rheumatology, University of Nebraska Medical Center, Omaha, NE, 3Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, 4Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 5Albany Medical Center, Albany, NY, 6Columbia University, New York, NY, 7Corrona, LLC, Waltham, MA, 8Stanford University, Palo Alto, CA, 9University of Alabama at Birmingham, Birmingham, AL, 10University of Nebraska Medical Center, Omaha, NE

    Background/Purpose:  Although biologics represent a major advance in rheumatoid arthritis (RA), many patients fail to achieve adequate responses to these agents.  As previous studies have…
  • Abstract Number: 2543 • 2018 ACR/ARHP Annual Meeting

    Retention Rate and Safety Data of Biosimilar CT-P13 in Patients with Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry

    Hyoun-Ah Kim1, Eun-Young Lee2, Sun Kyung Lee3, Yong-Beom Park4, Young Nam Lee5, HeeJung Kang6 and Kichul Shin7, 1Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), 2Department of Medical Informatics, Ajou University School of Medicine, Suwon, Korea, Republic of (South), 3Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), 4Yonsei University College of Medicine, Seoul, Korea, Republic of (South), 5Celltrion Healthcare Co. Ltd, Incheon, Korea, Republic of (South), 6Celltrion Healthcare Co.Ltd, Incheon, Korea, Republic of (South), 7Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South)

    Background/Purpose: CT-P13 is a biosimilar prescribed in a number of countries for indications approved for the reference infliximab (RINF) including rheumatoid arthritis (RA), ankylosing spondylitis…
  • Abstract Number: 579 • 2018 ACR/ARHP Annual Meeting

    Changes in DNA Methylation Identify Response to Treatment with Methotrexate and TNF Inhibitors Among RA Patients

    Cameron Adams1, Katie Marker1, Melissa Krueger2, Lisa Barcellos1 and Lindsey A. Criswell3, 1School of Public Health, UC Berkeley, Berkeley, CA, 2UC San Francisco, San Francisco,, CA, 3University of California San Francisco, San Francisco, CA

    Background/Purpose: Epigenetic modifications including DNA methylation are implicated in the development and progression of autoimmune diseases, such as rheumatoid arthritis  [MIM 180300]. Evidence indicates that…
  • Abstract Number: 2549 • 2018 ACR/ARHP Annual Meeting

    Patient-Reported Benefits of Sarilumab Monotherapy in Adult Patients with Active Rheumatoid Arthritis: Results from an Open-Label Extension Study

    Vibeke Strand1, Matthew Reaney2, Erin Mangan3, Hubert van Hoogstraten4, Susan Boklage3 and Chih-Chi Hu5, 1Stanford University School of Medicine, Palo Alto, CA, 2Sanofi, Guildford, United Kingdom, 3Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 4Sanofi Genzyme, Bridgewater, NJ, 5Sanofi, Bridgewater, NJ

    Background/Purpose: Sarilumab is a human monoclonal antibody that binds to membrane and soluble IL-6R, which is approved for the treatment of moderate to severe rheumatoid…
  • 1
  • 2
  • 3
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences